Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis.
Saved in:
| Title: | Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. |
|---|---|
| Authors: | Evans, Denise1 (AUTHOR) devans@heroza.org, Hirasen, Kamban1,2 (AUTHOR), Ramushu, Clive1 (AUTHOR), Long, Lawrence1,3 (AUTHOR), Sinanovic, Edina2 (AUTHOR), Conradie, Francesca4 (AUTHOR), Howell, Pauline4 (AUTHOR), Padanilam, Xavier5 (AUTHOR), Ferreira, Hannetjie6 (AUTHOR), Variaiva, Ebrahim6 (AUTHOR), Rajaram, Shakira4 (AUTHOR), Gupta, Aastha7 (AUTHOR), Juneja, Sandeep7 (AUTHOR), Ndjeka, Norbert8 (AUTHOR) |
| Source: | PLoS ONE. 10/21/2024, Vol. 19 Issue 10, p1-19. 19p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
